Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14.

PMID:
29907599
2.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V.

Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

3.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.

PMID:
29047142
4.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.

PMID:
28843184
5.

Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis.

Kovarik JJ, Kernbauer E, Hölzl MA, Hofer J, Gualdoni GA, Schmetterer KG, Miftari F, Sobanov Y, Meshcheryakova A, Mechtcheriakova D, Witzeneder N, Greiner G, Ohradanova-Repic A, Waidhofer-Söllner P, Säemann MD, Decker T, Zlabinger GJ.

PLoS One. 2017 Jul 24;12(7):e0180900. doi: 10.1371/journal.pone.0180900. eCollection 2017.

6.

Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses.

Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T.

Front Immunol. 2017 Jan 26;8:29. doi: 10.3389/fimmu.2017.00029. eCollection 2017. Review.

7.

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; FIRE-3 study investigators.

Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8.

8.

The Influence of Programmed Cell Death in Myeloid Cells on Host Resilience to Infection with Legionella pneumophila or Streptococcus pyogenes.

Gamradt P, Xu Y, Gratz N, Duncan K, Kobzik L, Högler S, Kovarik P, Decker T, Jamieson AM.

PLoS Pathog. 2016 Dec 14;12(12):e1006032. doi: 10.1371/journal.ppat.1006032. eCollection 2016 Dec. Erratum in: PLoS Pathog. 2017 Aug 30;13(8):e1006591.

9.

STAT1 regulates marginal zone B cell differentiation in response to inflammation and infection with blood-borne bacteria.

Chen TT, Tsai MH, Kung JT, Lin KI, Decker T, Lee CK.

J Exp Med. 2016 Dec 12;213(13):3025-3039. Epub 2016 Nov 14.

10.

Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions.

Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, Saluzzo S, Quattrone F, Gawish R, Lakovits K, Aichinger MC, Radic-Sarikas B, Lardeau CH, Hladik A, Korosec A, Brown M, Vaahtomeri K, Duggan M, Kerjaschki D, Esterbauer H, Colinge J, Eisenbarth SC, Decker T, Bennett KL, Kubicek S, Sixt M, Superti-Furga G, Knapp S.

Nat Immunol. 2016 Dec;17(12):1361-1372. doi: 10.1038/ni.3590. Epub 2016 Oct 31.

PMID:
27798618
11.

Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.

Oncoimmunology. 2016 May 19;5(9):e1186314. eCollection 2016.

12.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group.

Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27.

PMID:
27234640
13.

The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate.

Tortola L, Nitsch R, Bertrand MJM, Kogler M, Redouane Y, Kozieradzki I, Uribesalgo I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, Hanada T, Takahashi N, Kernbauer E, Demiröz D, Lang M, Superti-Furga G, Decker T, Pichler A, Ikeda F, Kroemer G, Vandenabeele P, Sorensen PH, Penninger JM.

Cell Rep. 2016 May 17;15(7):1481-1492. doi: 10.1016/j.celrep.2016.04.032. Epub 2016 May 5. Erratum in: Cell Rep. 2016 Sep 20;16(12 ):3414.

14.

Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation.

Decker T.

EMBO J. 2016 Mar 15;35(6):555-7. doi: 10.15252/embj.201693974. Epub 2016 Feb 18. No abstract available.

15.

Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1.

Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T.

EMBO Rep. 2016 Mar;17(3):367-82. doi: 10.15252/embr.201540726. Epub 2016 Feb 12.

16.

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

Cserni G, Wells CA, Kaya H, Regitnig P, Sapino A, Floris G, Decker T, Foschini MP, van Diest PJ, Grabau D, Reiner A, DeGaetano J, Chmielik E, Cordoba A, Andreu X, Zolota V, Charafe-Jauffret E, Ryska A, Varga Z, Weingertner N, Bellocq JP, Liepniece-Karele I, Callagy G, Kulka J, Bürger H, Figueiredo P, Wesseling J, Amendoeira I, Faverly D, Quinn CM, Bianchi S.

Virchows Arch. 2016 Apr;468(4):473-81. doi: 10.1007/s00428-016-1909-x. Epub 2016 Jan 27.

PMID:
26818833
17.

Intestinal Microbiota Signatures Associated with Inflammation History in Mice Experiencing Recurring Colitis.

Berry D, Kuzyk O, Rauch I, Heider S, Schwab C, Hainzl E, Decker T, Müller M, Strobl B, Schleper C, Urich T, Wagner M, Kenner L, Loy A.

Front Microbiol. 2015 Dec 15;6:1408. doi: 10.3389/fmicb.2015.01408. eCollection 2015.

18.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
19.

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.

Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M.

Breast Care (Basel). 2015 Jul;10(3):211-9. doi: 10.1159/000433590. Epub 2015 Jun 23.

20.

Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.

Hainzl E, Stockinger S, Rauch I, Heider S, Berry D, Lassnig C, Schwab C, Rosebrock F, Milinovich G, Schlederer M, Wagner M, Schleper C, Loy A, Urich T, Kenner L, Han X, Decker T, Strobl B, Müller M.

J Immunol. 2015 Nov 15;195(10):5011-24. doi: 10.4049/jimmunol.1402565. Epub 2015 Oct 2.

Supplemental Content

Loading ...
Support Center